Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 10;8(3):e44.
doi: 10.1002/hem3.44. eCollection 2024 Mar.

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation

Adrien Caillet  1 , Marion Simonet-Boissard  1 , Edouard Forcade  2 , Marie Robin  3 , Marie-Thérèse Rubio  4 , Marie-Anne Couturier  5 , Micha Srour  6 , Natacha Maillard  7 , Raynier Devillier  8 , Anne Huynh  9 , Jean-Henri Bourhis  10 , Célestine Simand  11 , Sylvain Chantepie  12 , Cyril Boisson  13 , Marie Kroemer  14 , Eric Deconinck  15 , Ana Berceanu  1
Affiliations

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation

Adrien Caillet et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Duration of ivosidenib and combination treatment. (B) Overall survival (C) Overall survival regarding response. (D) Progression‐free survival. (E) Progression‐free survival regarding response. AlloHCT, allogeneic hematopoietic cell transplantation; CR, complete response; CRi, complete response with incomplete hematologic recovery; DLI, donor lymphocyte infusion; NE, not evaluable.
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. - PubMed
    1. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424‐447. - PMC - PubMed
    1. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53‐61. - PMC - PubMed
    1. Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non‐identical family donors. Haematologica. 2022;107(5):1045‐1053. - PMC - PubMed
    1. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454‐459. - PMC - PubMed